Table 2:
Prevalence and incidence of HIV, prevalence of viral suppression and high viral load, and 95–95–95 targets among men and women aged 15–64 years in the 2015−16 and 2020−21 Malawi Population-based HIV Impact Assessments
| 2015–16 |
2020–21 |
Risk ratio comparing surveys (95% CI) | p value | |||
|---|---|---|---|---|---|---|
| n | Weighted proportion (95% CI) | n | Weighted proportion (95% CI) | |||
| HIV prevalence | ||||||
| Total | 17 187 | 10·6% (10·0–11·2) | 21 208 | 8·9% (8·4–9·5) | 0·85 (0·78–0·92) | <0·0001 |
| Women | 9979 | 12·5% (11·7–13·4) | 12 255 | 10·6% (10·0–11·2) | 0·85 (0·78–0·93) | 0·0010 |
| Men | 7208 | 8·5% (7·8–9·3) | 8953 | 7·1% (6·5–7·7) | 0·83 (0·74–0·94) | 0·0040 |
| Annual HIV incidence | ||||||
| Total | 17 187 | 0·37% (0·20–0·53) | 21 208 | 0·22% (0·11–0·34) | 0·61 (0·31–1·20) | 0·15 |
| Women | 9979 | 0·50% (0·25–0·75) | 12 255 | 0·31% (0·13–0·48) | 0·62 (0·29–1·32) | 0·21 |
| Men | 7208 | 0·23% (0·04–0·43) | 8953 | 0·13% (0·00–0·29) | 0·57 (0·13–2·47) | 0·45 |
| High viral load prevalence | ||||||
| Total | 17 187 | 3·3% (3·1–3·6) | 21 208 | 1·2% (1·0–1·3) | 0·35 (0·29–0·41) | <0·0001 |
| Women | 9979 | 3·4% (3·0–3·8) | 12 255 | 1·3% (1·1–1·5) | 0·37 (0·30–0·46) | <0·0001 |
| Men | 7208 | 3·3% (2·9–3·8) | 8953 | 1·1% (0·9–1·3) | 0·32 (0·25–0·41) | <0·0001 |
| Population viral load suppression | ||||||
| Total | 2220 | 68·3% (66·0–70·7) | 2337 | 87·0% (85·3–88·5) | 1·27 (1·22–1·32) | <0·0001 |
| Women | 1508 | 73·1% (70·3–75·7) | 1614 | 88·2% (86·3–89·9) | 1·21 (1·16–1·26) | <0·0001 |
| Men | 712 | 60·9% (56·8–64·9) | 723 | 85·0% (82·2–87·5) | 1·40 (1·30–1·50) | <0·0001 |
| First 95: awareness | ||||||
| Total | 2217 | 76·8% (74·7–79·0) | 2337 | 88·4% (86·7–90·0) | 1·15 (1·11–1·19) | <0·0001 |
| Women | 1505 | 80·2% (77·7–82·4) | 1614 | 90·4% (88·4–92·0) | 1·13 (1·09–1·17) | <0·0001 |
| Males | 712 | 71·7% (67·6–75·4) | 723 | 85·2% (81·9–88·0) | 1·19 (1·11–1·27) | <0·0001 |
| Second 95: on antiretroviral therapy | ||||||
| Total | 1720 | 91·4% (89·8–93·0) | 2096 | 97·8% (97·1–98·5) | 1·07 (1·05–1·09) | <0·0001 |
| Women | 1210 | 92·9% (91·2–94·6) | 1473 | 98·1% (97·3–98·8) | 1·06 (1·03–1·08) | <0·0001 |
| Men | 510 | 88·7% (85·1–91·6) | 623 | 97·3% (95·8–98·8) | 1·10 (1·05–1·14) | <0·0001 |
| Third 95: viral load suppression | ||||||
| Total | 1564 | 91·3% (89·1–93·1) | 2055 | 96·9% (95·9–97·7) | 1·06 (1·04–1·09) | <0·0001 |
| Women | 1110 | 92·1% (89·6–94·0) | 1446 | 97·0% (95·7–97·9) | 1·05 (1·03–1·08) | <0·0001 |
| Men | 454 | 89·8% (85·6–92·9) | 609 | 96·8% (95·0–98·0) | 1·08 (1·03–1·12) | <0·0001 |